Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland.
The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies.
“We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collaboration will generate novel drugs that benefit cancer patients.”
BioCopy will use Biocytogen’s TCR-mimic antibodies and test them against promising intracellular tumor associated antigens. Here, BioCopy will use its automated end-to-end platform for the optimization of multispecific biotherapeutics to further develop these TCR-mimic antibodies into next-generation oncological drugs.
About Biocytogen’s TCR-mimic Antibody Discovery Platform
Biocytogen’s TCR-mimic platform focuses on the discovery of fully human antibodies to intracellular targets that are presented on the cell surface by MHC class I molecules. Leveraging proprietary RenTCR-mimicTM (HLA/RenMab) mice and specialized immunization protocols, Biocytogen’s platform is designed to generate TCR-mimic antibodies that are highly specific for peptide/HLA complexes and not HLA itself. Using a high-throughput antibody screening platform, Biocytogen swiftly identifies TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients to overcome tumor immune escape. Currently, antibody hits for multiple intracellular targets, including TAAs, cancer-testis antigens, mutated protein antigens, and viral protein antigens, are being evaluated in vivo and in vitro. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), the USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About BioCopy
BioCopy is a multinational company headquartered in Switzerland with a state-of-the-art R&D facility in Germany. The company focuses on biotherapeutic drug discovery and development using their end-to-end automated, AI-powered platform. BioCopy is convinced that cancer can be cured with ingenuity and AI, supported by the extraordinary power of our body’s own immune system. With the company’s unique platform, BioCopy is working continuously to develop next-generation biotherapeutic drug candidates with unprecedented efficacy and safety, transforming today’s pharmaceutical industries.
Website: www.biocopy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506586492/en/
Contact information
Biocytogen
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Electricity and Water Authority PJSC Reports a Record AED 14.6 Billion in Revenue for the First Half of 2025 and Approves Dividend Payment of AED 3.1 Billion8.8.2025 18:47:00 EEST | Press release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its first half 2025 consolidated financial results, recording first half revenue of AED 14.6 billion, EBITDA of AED 7.0 billion, operating profit of AED 3.7 billion, net profit of AED 2.9 billion and cash from operations of AED 9.2 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808832927/en/ Dubai Electricity and Water Authority PJSC reports a record AED 14.6 billion in revenue for the first half of 2025 and approves dividend payment of AED 3.1 billion (Graphic: AETOSWire) “DEWA is committed to be an innovative and sustainable corporation inspired by the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the directives of His Highn
Philippine Government and Sutherland Launch AI Academy to Equip Filipinos with Future-Ready Skills8.8.2025 16:54:00 EEST | Press release
Sutherland, a global leader in business and digital transformation, has partnered with the Philippine Government to launch a dedicated AI Academy. This strategic initiative supports the Philippine government’s broader efforts to empower the Filipino workforce for an AI-driven future. The AI Academy will offer practical, industry-aligned training designed to equip Filipino professionals with skills to integrate artificial intelligence into their work. It aims to strengthen the country’s talent pool by developing capabilities that are increasingly in demand across sectors, whether as AI specialists, prompt engineers, or cybersecurity professionals. The program will prepare participants to harness AI in driving productivity, advancing innovation, and pursuing high-value opportunities across industries. “This initiative is a vital step toward our goal of building a digitally resilient and inclusive workforce, said President Ferdinand R. Marcos Jr. “By expanding access to training in future
Baraja Appoints IP Pioneer to Lead Global Sale of Spectrum-Scan™ LiDAR IP Assets8.8.2025 16:00:00 EEST | Press release
Baraja Pty Ltd (“Baraja”), the Australian pioneer behind the revolutionary Spectrum‑Scan™ LiDAR architecture, has announced a global initiative to commercialize its full suite of patented LiDAR intellectual property and technical assets. The company has appointed IP Pioneer Group Incas the exclusive worldwide advisor to manage this competitive transaction process. Baraja redefined LiDAR performance through its Spectrum-Scan™ technology—a transformative solid-state architecture that steers the laser beam by tuning its wavelength through a dispersive prism or grating, eliminating moving parts. This breakthrough enables long-range, high-resolution 3D sensing that is inherently immune to alignment drift, sunlight, and multi-LiDAR interference. Having achieved significant technical milestones in LiDAR innovation, Baraja is now strategically evolving its business focus to pursue new frontiers in sensing and perception. This initiative will allow a new commercial partner to capitalize on the
Graanul - Expiry of Early Consent Deadline relating to the Consent Solicitation and Scheme Solicitation8.8.2025 13:54:00 EEST | Press release
Graanul: Expiry of Early Consent Deadline relating to the Consent Solicitation and Scheme Solicitation for Graanul’s: €250,000,000 Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354015 / Common Code 239735401 Rule 144A Notes: ISIN Number XS2397354288 / Common Code 239735428) (the “Existing Floating Rate Notes”) and €380,000,000 4.625% Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354528 / Common Code 239735452 Rule 144A Notes: ISIN Number: XS2397355095 / Common Code 239735509) (the “Existing Fixed Rate Notes” and, together with the Existing Floating Rate Notes, the “Existing Notes”) of Cullinan Holdco SCSp a special limited partnership (société en commandite spéciale) established under the laws of Luxembourg, having its registered office at 2, avenue Charles de Gaulle, L-1653, registered with the Luxembourg Register of Commerce and Companies under number B-256979 (the “Issuer” and tog
Traka Celebrates 30 Years of Innovation in Intelligent Key and Asset Management8.8.2025 12:00:00 EEST | Press release
Traka, an ASSA ABLOY company and global leader in intelligent key and equipment management solutions, is excited to announce its 30 years of innovation in intelligent key and asset management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808492250/en/ Traka is celebrating its 30th anniversary this year after its inception in 1995. What began as a custom solution for British Airways has grown into a global leader in intelligent key and asset management. Traka, now celebrating its 30th anniversary, is marking three decades of innovation, expansion, and impact across more than 30 industries worldwide. In 1995, Traka’s founder, John Kent, responded to a unique challenge: British Airways needed a secure and trackable way to manage critical keys, something the market didn’t yet offer. Kent built the first Traka key cabinet, setting the foundation for what would become a new category in access management. That first electronic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom